Roughly 383 clinical trials had their NIH grants terminated between late February and August of this year, and that number sits at the center of what WCG’s 2025 Clinical Research Site Challenges Report frames as an accelerating structural crisis for research sites. The report, released this week, surveys the pressures bearing down on sites from multiple directions at once: funding volatility, rising protocol complexity, constrained capacity, and start-up friction that compounds every other problem. The picture it draws is not one of isolated setbacks but of a site ecosystem operating closer to its limits than sponsors and CROs typically acknowledge in their planning assumptions.
The funding dimension is the most acute near-term threat. Federal terminations of approximately 2,300 NIH grants totaling nearly $3.8 billion have disrupted trials in oncology, HIV/AIDS, and chronic disease, stripping sites of the predictable revenue that sustains research infrastructure between commercial studies. Academic medical centers and community sites hit by those cancellations do not simply absorb the loss and wait. They reduce research staff, shrink coordinator capacity, and become harder to activate for the next industry-sponsored protocol. WCG’s report specifically flags trial pauses and cancellations as a trend line sponsors need to internalize, not treat as one-off events.
Protocol complexity is the slower, quieter pressure. Sites are being asked to execute trials with more procedures, tighter visit windows, and broader data capture requirements, while investigator turnover driven by workload and reporting burdens keeps eroding the experienced personnel needed to absorb that complexity. The FDA has separately pushed sponsors toward broader eligibility criteria and more flexible enrollment practices, which is the right direction scientifically but adds operational demands on sites already stretched thin. Expanding who can enroll means more screening, more heterogeneous populations, and more burden on coordinators who may not yet exist at the sites being asked to do the work.
WCG positions the report as a resource for sponsors and CROs, not just sites, which signals where the report’s real argument lands: site fragility is now a sponsor risk. The one concrete number to track from here is coordinator vacancy rates at sites participating in federally funded research. If those rates climb through the end of 2025, commercial trial timelines will feel it in 2026 activation windows, regardless of how well a sponsor’s protocol is designed.
Source link: https://cms.centerwatch.com/insights/2025-clinical-research-site-challenges-report/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
